Holen Sie sich die Stockscreener-App
46.63
1.04%
-0.49
Handel nachbörslich:
46.70
0.07
+0.15%
Schlusskurs vom Vortag:
$47.12
Offen:
$47.07
24-Stunden-Volumen:
19.71M
Relative Volume:
0.67
Marktkapitalisierung:
$10.15B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
67.58
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-1.75%
1M Leistung:
-21.13%
6M Leistung:
+33.08%
1J Leistung:
+109.67%
1-Tages-Spanne:
$46.03
$48.45
1-Wochen-Bereich:
$46.03
$50.99
52-Wochen-Spanne:
$18.32
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
46.63 | 10.65B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
143.94 | 64.44B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.77 | 44.53B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.05 | 40.61B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.23 | 22.69B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
455.32 | 18.78B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc. - PR Newswire
Best Healthcare Stocks To Add to Your WatchlistOctober 29th - MarketBeat
Can Sustained Product Demand Drive HIMS Stock Before Q3 Earnings? - Yahoo Finance
Hims to begin selling GLP-1 microdosing treatments - Sherwood News
Microdosing Treatment Plans for Metabolic Health - Hims & Hers Newsroom
1 Profitable Stock on Our Watchlist and 2 We Find Risky - The Globe and Mail
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Hims & Hers Health Stock (HIMS) Opinions on Menopause Care Launch - Quiver Quantitative
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now? - sharewise.com
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Is Hims & Hers Health Still a Smart Opportunity After 124% Stock Surge in 2025? - Yahoo Finance
Hims & Hers: Pioneering Customer-Centric Innovation with Premium Valuation - FXLeaders
Hims & Hers: Use This Drop Before It's Too Late (NYSE:HIMS) - Seeking Alpha
Hims & Hers Short Interest Nears All-Time High, Buy The Dip? - MarketBeat
Menopause Care Expansion Could Be a Game Changer for Hims & Hers Health (HIMS) - simplywall.st
Shattering the Stigma around Menopause with Molly Sims in New York City - Hims & Hers Newsroom
Telehealth Stock Could Rebound Off Long-Term Trendline - Schaeffer's Investment Research
Hims & Hers: There's Opportunity In This Crash (Upgrade) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) Stock forecasts - Yahoo
1 Mid-Cap Stock Worth Your Attention and 2 We Avoid - The Globe and Mail
Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - Insider Monkey
Why Hims & Hers Stock Slipped Today - AOL.com
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
The Problems We’re Solving in Healthcare - Hims & Hers Newsroom
Hims & Hers Advances AI-Powered Personalized Digital Healthcare - Yahoo Finance
Could Hims & Hers Health's (HIMS) Menopause Expansion Reveal a New Competitive Edge in Women's Care? - Yahoo Finance
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026 - Fitt Insider
Hers Health Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Hims & Hers (HIMS) Faces Margin Concerns Amid Growth Plans - GuruFocus
CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You? - Barchart.com
Hims & Hers rated Sector Weight at KeyBanc on margin worries - Seeking Alpha
HIMS Stock Declines Despite Launch of New Specialty in Women's Health - Yahoo Finance
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance (HIMS) - Seeking Alpha
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
HIMS: Keybanc Initiates Coverage with 'Sector Weight' Rating | H - GuruFocus
Hers Health Inc. (82W) stock expanding market penetrationPortfolio Update Report & Precise Buy Zone Identification - newser.com
Investor Mood: Hers Health Inc. stock undervalued after correctionLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright - Seeking Alpha
Hims & Hers CFO Okupe sells $662k in shares - Investing.com
Hims & Hers Health CFO Sells Shares Under Trading Plan - TradingView
HIMS CFO exercises options, sells 11,592 shares under Rule 10b5-1 - Stock Titan
Hims & Hers Health (HIMS) Stock Is Up, What You Need To Know - Yahoo Finance
Hims & Hers Health: Roller Coaster Gift (NYSE:HIMS) - Seeking Alpha
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Hers Health Inc.July 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Avoiding Lag: Real-Time Signals in (HIMS) Movement - news.stocktradersdaily.com
Hims & Hers Health (HIMS): How the Menopause Launch Shapes Valuation and Growth Expectations - Yahoo Finance
Should the New Menopause Specialty and CEO Share Sale Prompt a Closer Look at HIMS? - simplywall.st
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.15%
2.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):